Henri Lichenstein

Shanghai Bioveda Investment Management Consulting Co. Ltd. (BioVeda China) is an independent Chinese venture capital firm which was established by Dr. Zhi Yang when BioVeda Capital spun off their China Fund. Headquartered in Shanghai, BioVeda China is the first international life science venture capital firm in China and manages the BioVeda China Fund, backed by blue chip international institutional and corporate investors. The firm's Scientific Advisory Board, comprised of international experts from China and the West, supports BioVeda China by acting as a business and scientific bridge between companies in China and the West, linking finance and technology between the two markets.

CARsgen Therapeutics Co., Ltd. develops an immunotherapy cancer treatment. It develops a novel cell-based immunotherapy using T-cells carrying chimeric antigen receptor technology for cancer treatment. The company was founded by ZongHai Li in 2014 and is headquartered in Shanghai, China.

Part of Shanghai Bioveda Investment Management Consulting Co. Ltd., BVCF Investment Consulting (Shanghai) Ltd. is a healthcare investment company based in Shanghai, China. BVCF actively assists business owners and entrepreneurs to build their companies into world-class businesses. The Chinese company has raised five funds and invests in growth-stage healthcare companies from around the world, with a particular focus on innovative solutions that address unmet health needs. The company was founded by Zhi Yang and Ya Chao Zhao has been the CEO of the company since 2007.